Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-year safety and tolerability study of cariprazine in adolescents with schizophrenia
2024-513222-30-00Phase 3Completed
- Sponsor
- Gedeon Richter Plc
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of cariprazine in schizophrenia, sponsored by Gedeon Richter Plc. Primary endpoint: Safety and tolerability outcomes. Started Jul 2024; status: completed.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-513222-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513222-30-00.